EU greenlights VentriPoint's heart disease monitor
The European Union has granted heart disease monitoring systems developer VentriPoint Diagnostics CE mark approval for its VentriPoint Medical System (VMS).

According to the Seattle-based Company, the VMS generates a rapid right ventricle function assessment from a 2D ultrasound, a critical measurement for cardiovascular disease patients.

With the CE Mark, VentriPoint will have the ability to vend its VMS product globally. The device has already received Health Canada clearance and the submission to the FDA for U.S. approval was recently filed.